272 Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study | International Journal of Gynecologic Cancer
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer - Plain Language Summaries
PDF) 76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
From New Molecular Insights to New Treatment Options in Endometrial Cancer | Published in healthbook TIMES Oncology Hematology
Cancer Trial Results
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis - Gynecologic Oncology
Dostarlimab Shows Durable Antitumor Activity in GARNET Trial Expansion Cohorts With Advanced, Recurrent Endometrial Cancer
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I ...
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer | Future Oncology
Antitumor Activity of Dostarlimab in Patients with Mismatch Repair–Deficient (dMMR) Tumors: a Combined Analysis of 2 Cohorts i
Expert Commentary On The Product Profile Of Dostarlimab
Biomolecules | Free Full-Text | Dostarlimab: A Review
GARNET Study Suggests Dostarlimab Promising for Uterine/Endometrial Cancer - CancerConnect
Dostarlimab in Advanced/Recurrent Mismatch Repair Deficient/Microsatellite Instability High or Proficient/Stable Endometrial Can
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in
Cancer Trial Results
Plain language summary of the GARNET trial: clinical activity and safety of dostarlimab for recurrent or advanced dMMR endometrial cancer patients - Oncology Central
Biosensors | Free Full-Text | Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment
Current Oncology | Free Full-Text | Endometrial Cancer: Transitioning from Histology to Genomics
Dostarlimab: First Approval | SpringerLink
Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study - ScienceDirect
Dostarlimab subject to accelerated FDA approval for the treatment of advanced dMMR endometrial cancer | VJOncology
GSK announces positive data for endometrial cancer drug dostarlimab - Pharmaceutical Technology
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001 | International Journal of Gynecologic Cancer
